FDA’s Pharmacy Compounding Advisory Committee (PCAC) will meet on March 8 and 9
to discuss whether to allow a new group of substances to be compounded. Substances
under consideration include boswellia (an anti-inflammatory that can be used to
treat arthritis and osteoarthritis), aloe vera (treats everything from burns to
constipation, psoriasis, and herpes simplex virus), d-ribose (increases energy
production and can rejuvenate heart muscles after a heart attack), chondroitin
sulfate (stimulates the production of cartilage, improves blood circulation to
the joints, and treats osteoarthritis), and acetyl-L-carnitine, an antioxidant
that is used for Alzheimer’s and age-related memory problems).
are commonly available supplements, yet the committee seems to think that
everyday supplements should be banned from compounding. This is completely
illogical. Send a message to the PCAC urging them to approve the ingredients that
have been nominated to the Bulk Ingredient List—and send a copy to Congress as
well. Your legislators need to see what is happening to their compounding law!
Please personalize and add your own
comments if you have time!
Please Approve the Compounding Bulk Ingredient Nominations
Dear [Decision Maker],
Sincerely,[Your Name] [Your Address] [City, State ZIP]